S&P/ASX 200 Index (ASX: XJO) shares are in the red for 2026, down 1.2% so far.
Experts say some ASX shares are likely to defy current market trends.
Let's take a look at seven shares with buy ratings and ambitious 12-month price targets from the professionals.
Champion Iron Ltd (ASX: CIA)
The Champion Iron share price closed at $4.25 on Friday.
The ASX 200 iron ore small-cap share has lost 31% of its valuation in 2026.
RBC Capital has confidence this stock can turn it around.
The broker has a buy rating and an $8.07 price target, suggesting 90% growth over the next 12 months.
Brambles Ltd (ASX: BXB)
The Brambles share price closed last week at $16.92.
This ASX 200 industrial share has tumbled 26% in 2026 so far.
RBC Capital has hope for Brambles shares.
The broker reiterates its buy rating with a $27 price target.
This indicates a potential near-60% upside ahead.
Iperionx Ltd (ASX: IPX)
The Iperion share price finished Friday's session at $5.43.
This ASX materials share is down 6.2% in the calendar year to date (YTD).
Bell Potter maintains its buy rating with an $8.25 price target.
This implies a potential 52% upside ahead.
Megaport Ltd (ASX: MP1)
The Megaport share price closed last week at $18.48 apiece.
This ASX 200 tech share is up 50% so far in 2026.
Megaport shares ripped 19% last week and set a 52-week high of $21.16 on Friday.
The share price surge followed news of four new AI infrastructure contracts worth $458.9 million.
To fund the capex requirements for the new work, Megaport launched a fully underwritten $827.3 million entitlement offer.
Macquarie retains its buy rating and lifted its 12-month target from $26.30 to $27.80.
This implies potential capital gains of 50% ahead.
Qantas Airways Ltd (ASX: QAN)
The Qantas share price finished last week at $9.19.
The ASX 200 airline share has dropped 12.4% YTD.
Goldman Sachs renewed its buy rating on Qantas with a $12.25 share price target.
This implies a potential 33% increase over the next 12 months.
Pro Medicus Ltd (ASX: PME)
The Pro Medicus share price closed at $165.64 last week.
Macquarie maintains its buy rating on this ASX 200 healthcare share with a $221 target.
This suggests a potential 33% upside ahead.
Newmont Corporation CDI (ASX: NEM)
The Newmont share price finished at $148.76 on Friday.
This ASX 200 gold share has dipped 1.6% in 2026 while the gold price has lifted 3.3%.
UBS has a buy rating on Newmont shares with a 12-month target of $195.
This suggests a possible 31% upside ahead.
The post 7 ASX shares set to soar 30% to 90% in 12 months: experts appeared first on The Motley Fool Australia.
Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group, Macquarie Group, and Megaport. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026